| Assessment Status | Rapid Review Complete |
| HTA ID | 21059 |
| Drug | Pembrolizumab |
| Brand | Keytruda® |
| Indication | In combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) in adults whose tumours express PD-L1 with a combined positive score (CPS) ≥ 10 and who have not received prior chemotherapy for metastatic disease. |
| Assessment Process | |
| Rapid review commissioned | 29/11/2021 |
| Rapid review completed | 13/01/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab in combination with chemotherapy compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
